Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 5, 2010, Pages 658-664

  Ghobrial, Oliver ^a,b   Derendorf, Hartmut ^b   Hillman, Jeffrey D ^a  

^a Oragenics Inc   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Lanthionine; Lantibiotic; MRSA; MU1140; Pharmacodynamics; Protein binding; Streptococcus mutans; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; GALLIDERMIN; LANTIBIOTIC; MU 1140; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; BLOOD PROTEINS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROTEIN BINDING; SERUM; SPECIES SPECIFICITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 78349309060     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.09.005     Document Type: Article

References (28)

1. Beer J., Wagner C.C., Zeitlinger M. Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing. AAPS J. 2009.
2. Calain P., Krause K.H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J. Infect. Dis. 1987, 155:187-191.
3. Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand. J. Infect. Dis. Suppl. 1990, 74:23-33.
4. Chambers H.F., Mills J., Drake T.A., Sande M.A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev. Infect. Dis. 1984, 6(Suppl. 4):S870-S874.
5. Chatterjee C., Paul M., Xie L., van der Donk W.A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 2005, 105:633-684.
6. Craig W.A, Ebert S.C. Protein binding and its significance in antibacterial therapy. Infect. Dis. Clin. North Am. 1989, 3:407-414.
7. Craig W.A., Kunin C.M. Significance of serum protein and tissue binding of antimicrobial agents. Annu. Rev. Med. 1976, 27:287-300.
8. Dykhuizen R.S., Harvey G., Stephenson N., Nathwani D., Gould I.M. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob. Agents Chemother. 1995, 39:1842-1847.
9. Ghobrial O.G., Derendorf H., Hillman J.D. Pharmacodynamic activity of the lantibiotic MU1140. Int. J. Antimicrob. Agents 2009, 33:70-74.
10. Ghobrial O.G., Derendorf H., Hillman J.D. Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. J. Pharm. Biomed. Anal. 2009, 49:970-975.
11. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353:38-52.
12. Guttler F., Tybring L., Engberg-Pedersen H. Interaction of albumin and fusidic acid. Br. J. Pharmacol. 1971, 43:151-160.
13. Hasper H.E., Kramer N.E., Smith J.L., Hillman J.D., Zachariah C., Kuipers O.P., de Kruijff B., Breukink E. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 2006, 313:1636-1637.
14. Hillman J.D, Novak J., Sagura E., Gutierrez J.A., Brooks T.A., Crowley P.J., Hess M., Azizi A., Leung K., Cvitkovitch D., Bleiweis A.S. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect. Immun. 1998, 66:2743-2749.
15. Jones R.N., Barry A.L. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum. Antimicrob. Agents Chemother. 1987, 31:818-820.
16. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
17. Kovar A., Dalla Costa T., Derendorf H. Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J. Pharm. Sci. 1997, 86:52-56.
18. Lam Y.W, Duroux M.H., Gambertoglio J.G., Barriere S.L., Guglielmo B.J. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob. Agents Chemother. 1988, 32:298-302.
19. Lee B.L, Sachdeva M., Chambers H.F. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 1991, 35:2505-2508.
20. Mueller M., de la Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 2004, 48:369-377.
21. Ogren S., Cars O. Importance of drug-protein interactions and protein concentrations for antibiotic levels in serum and tissue fluid. Scand. J. Infect. Dis. Suppl. 1985, 44:34-40.
22. Scaglione F., Demartini G., Arcidiacono M.M., Dugnani S., Fraschini F. Influence of protein binding on the pharmacodynamics of ceftazidime or ceftriaxone against gram-positive and gram-negative bacteria in an in vitro infection model. J. Chemother. 1998, 10:29-34.
23. Schmidt S., Schuck E., Kumar V., Burkhardt O., Derendorf H. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents; minimum inhibitory concentration versus time-kill curves. Expert. Opin. Drug Discov. 2007, 2:849-860.
24. Schmidt S, Rock K., Sahre M., Burkhardt O., Brunner M., Lobmeyer M.T., Derendorf H. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 2008, 52:3994-4000.
25. Smith L., Hillman J. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr. Opin. Microbiol. 2008, 11:401-408.
26. Smith L., Hasper H., Breukink E., Novak J., Cerkasov J., Hillman J.D., Wilson-Stanford S., Orugunty R.S. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 2008, 47:3308-3314.
27. Tompsett R., Shultz S., McDermott W. The Relation of protein binding to the pharmacology and antibacterial activity of penicillins X, G, dihydro F, and K. J. Bacteriol. 1947, 53:581-595.
28. Zhanel G.G., Kirkpatrick I.D., Hoban D.J., Kabani A.M., Karlowsky J.A. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 1998, 42:2427-2430.